501 related articles for article (PubMed ID: 28511795)
1. miR-142-5p regulates tumor cell PD-L1 expression and enhances anti-tumor immunity.
Jia L; Xi Q; Wang H; Zhang Z; Liu H; Cheng Y; Guo X; Zhang J; Zhang Q; Zhang L; Xue Z; Li Y; Da Y; Zhao P; Zhang R
Biochem Biophys Res Commun; 2017 Jun; 488(2):425-431. PubMed ID: 28511795
[TBL] [Abstract][Full Text] [Related]
2. miR-194-5p down-regulates tumor cell PD-L1 expression and promotes anti-tumor immunity in pancreatic cancer.
Wang C; Li X; Zhang L; Chen Y; Dong R; Zhang J; Zhao J; Guo X; Yang G; Li Y; Gu C; Xi Q; Zhang R
Int Immunopharmacol; 2021 Aug; 97():107822. PubMed ID: 34098485
[TBL] [Abstract][Full Text] [Related]
3. The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer.
Zhao L; Yu H; Yi S; Peng X; Su P; Xiao Z; Liu R; Tang A; Li X; Liu F; Shen S
Oncotarget; 2016 Jul; 7(29):45370-45384. PubMed ID: 27248318
[TBL] [Abstract][Full Text] [Related]
4. Long noncoding RNA LINC00473 drives the progression of pancreatic cancer via upregulating programmed death-ligand 1 by sponging microRNA-195-5p.
Zhou WY; Zhang MM; Liu C; Kang Y; Wang JO; Yang XH
J Cell Physiol; 2019 Dec; 234(12):23176-23189. PubMed ID: 31206665
[TBL] [Abstract][Full Text] [Related]
5. miR-142-5p regulates CD4+ T cells in human non-small cell lung cancer through PD-L1 expression via the PTEN pathway.
Wan J; Ling X; Peng B; Ding G
Oncol Rep; 2018 Jul; 40(1):272-282. PubMed ID: 29767245
[TBL] [Abstract][Full Text] [Related]
6. microRNA-20b-5p overexpression combing Pembrolizumab potentiates cancer cells to radiation therapy via repressing programmed death-ligand 1.
Jiang K; Zou H
Bioengineered; 2022 Jan; 13(1):917-929. PubMed ID: 34968160
[TBL] [Abstract][Full Text] [Related]
7. miR-105-5p regulates PD-L1 expression and tumor immunogenicity in gastric cancer.
Miliotis C; Slack FJ
Cancer Lett; 2021 Oct; 518():115-126. PubMed ID: 34098061
[TBL] [Abstract][Full Text] [Related]
8. [Plasma exosomal miR-335-5p serves as a diagnostic indicator and inhibits immune escape in triple-negative breast cancer].
Chen T; Dong Y; Wu X
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 Apr; 38(4):347-356. PubMed ID: 35583065
[TBL] [Abstract][Full Text] [Related]
9. MiR-195/-16 Family Enhances Radiotherapy via T Cell Activation in the Tumor Microenvironment by Blocking the PD-L1 Immune Checkpoint.
Tao Z; Xu S; Ruan H; Wang T; Song W; Qian L; Chen K
Cell Physiol Biochem; 2018; 48(2):801-814. PubMed ID: 30032144
[TBL] [Abstract][Full Text] [Related]
10. Serum exosomal miR-16-5p functions as a tumor inhibitor and a new biomarker for PD-L1 inhibitor-dependent immunotherapy in lung adenocarcinoma by regulating PD-L1 expression.
Chen HL; Luo YP; Lin MW; Peng XX; Liu ML; Wang YC; Li SJ; Yang DH; Yang ZX
Cancer Med; 2022 Jul; 11(13):2627-2643. PubMed ID: 35347894
[TBL] [Abstract][Full Text] [Related]
11. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-93-5p expression in tumor tissue and its tumor suppressor function via targeting programmed death ligand-1 in colorectal cancer.
Chen YL; Wang GX; Lin BA; Huang JS
Cell Biol Int; 2020 May; 44(5):1224-1236. PubMed ID: 32068322
[TBL] [Abstract][Full Text] [Related]
13. MiR-34a-5p/PD-L1 axis regulates cisplatin chemoresistance of ovarian cancer cells.
Zuo Y; Zheng W; Liu J; Tang Q; Wang SS; Yang XS
Neoplasma; 2020 Jan; 67(1):93-101. PubMed ID: 31777260
[TBL] [Abstract][Full Text] [Related]
14. The EGFR-P38 MAPK axis up-regulates PD-L1 through miR-675-5p and down-regulates HLA-ABC via hexokinase-2 in hepatocellular carcinoma cells.
Liu Z; Ning F; Cai Y; Sheng H; Zheng R; Yin X; Lu Z; Su L; Chen X; Zeng C; Wang H; Liu L
Cancer Commun (Lond); 2021 Jan; 41(1):62-78. PubMed ID: 34236149
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-140 suppresses osteosarcoma tumor growth by enhancing anti-tumor immune response and blocking mTOR signaling.
Ji X; Wang E; Tian F
Biochem Biophys Res Commun; 2018 Jan; 495(1):1342-1348. PubMed ID: 29170130
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-155 induction via TNF-α and IFN-γ suppresses expression of programmed death ligand-1 (PD-L1) in human primary cells.
Yee D; Shah KM; Coles MC; Sharp TV; Lagos D
J Biol Chem; 2017 Dec; 292(50):20683-20693. PubMed ID: 29066622
[TBL] [Abstract][Full Text] [Related]
17. Reactive oxygen species reprogram macrophages to suppress antitumor immune response through the exosomal miR-155-5p/PD-L1 pathway.
Li X; Wang S; Mu W; Barry J; Han A; Carpenter RL; Jiang BH; Peiper SC; Mahoney MG; Aplin AE; Ren H; He J
J Exp Clin Cancer Res; 2022 Jan; 41(1):41. PubMed ID: 35086548
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of PD-L1 predicts poor prognosis and is associated with miR-191-5p dysregulation in colon adenocarcinoma.
Chen XY; Zhang J; Hou LD; Zhang R; Chen W; Fan HN; Huang YX; Liu H; Zhu JS
Int J Immunopathol Pharmacol; 2018; 32():2058738418790318. PubMed ID: 30045644
[TBL] [Abstract][Full Text] [Related]
19. Bone marrow mesenchymal stromal cells attenuate liver allograft rejection may via upregulation PD-L1 expression through downregulation of miR-17-5p.
Chen Q; Zhou R; Zhang Y; Zhu S; Xiao C; Gong J; Li K; Tang H; Sun C; Zhang J
Transpl Immunol; 2018 Dec; 51():21-29. PubMed ID: 30092337
[TBL] [Abstract][Full Text] [Related]
20. A scoping review on the potentiality of PD-L1-inhibiting microRNAs in treating colorectal cancer: Toward single-cell sequencing-guided biocompatible-based delivery.
Shadbad MA; Asadzadeh Z; Derakhshani A; Hosseinkhani N; Mokhtarzadeh A; Baghbanzadeh A; Hajiasgharzadeh K; Brunetti O; Argentiero A; Racanelli V; Silvestris N; Baradaran B
Biomed Pharmacother; 2021 Nov; 143():112213. PubMed ID: 34560556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
